These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33508184)

  • 1. Targeting Pancreatic Ductal Adenocarcinoma (PDAC).
    Parrasia S; Zoratti M; Szabò I; Biasutto L
    Cell Physiol Biochem; 2021 Jan; 55(1):61-90. PubMed ID: 33508184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
    Tuerhong A; Xu J; Shi S; Tan Z; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Liang C
    Cell Mol Life Sci; 2021 Jul; 78(14):5505-5526. PubMed ID: 34131808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
    Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
    J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance.
    Chen H; Zhu X; Sun R; Ma P; Zhang E; Wang Z; Fan Y; Zhou G; Mao R
    Invest New Drugs; 2020 Dec; 38(6):1707-1716. PubMed ID: 32468271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
    Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.
    Coppola S; Carnevale I; Danen EHJ; Peters GJ; Schmidt T; Assaraf YG; Giovannetti E
    Drug Resist Updat; 2017 Mar; 31():43-51. PubMed ID: 28867243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
    Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
    Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
    Lafaro KJ; Melstrom LG
    Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma.
    Scianò F; Terrana F; Pecoraro C; Parrino B; Cascioferro S; Diana P; Giovannetti E; Carbone D
    Future Med Chem; 2024 Feb; 16(3):271-289. PubMed ID: 38269431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
    Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
    Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ABC transporters in PDAC - past, present, or future?
    Bergonzini C; Giovannetti E; Danen EHJ
    Oncotarget; 2024 Jun; 15():403-406. PubMed ID: 38900606
    [No Abstract]   [Full Text] [Related]  

  • 18. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
    Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
    Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
    Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sono-promoted drug penetration and extracellular matrix modulation potentiate sonodynamic therapy of pancreatic ductal adenocarcinoma.
    Xiao H; Li X; Li B; Zhong Y; Qin J; Wang Y; Han S; Ren J; Shuai X
    Acta Biomater; 2023 Apr; 161():265-274. PubMed ID: 36893956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.